VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
180.50
+2.23 (+1.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close178.27
Open178.35
Bid0.00 x 800
Ask0.00 x 1000
Day's Range177.90 - 181.60
52 Week Range127.67 - 181.60
Volume1,458,674
Avg. Volume1,659,652
Market Cap45.997B
Beta1.92
PE Ratio (TTM)204.19
EPS (TTM)0.88
Earnings DateJul 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est191.45
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Vertex to Announce Second Quarter 2018 Financial Results on July 25

    Vertex Pharmaceuticals Incorporated (VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

  • What’s behind Gemphire Therapeutics’ Stock Price Rise
    Market Realist6 days ago

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.

  • Incyte’s Valuations on July 6
    Market Realist6 days ago

    Incyte’s Valuations on July 6

    According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”

  • Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
    Motley Fool7 days ago

    Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

    The company's making progress, but competition could be fierce.

  • How Ionis Pharmaceuticals’ Valuation Compares
    Market Realist9 days ago

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.

  • Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?
    Market Realist10 days ago

    Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?

    In June, Health Canada approved Vertex Pharmaceuticals’ (VRTX) Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old who have two copies of the F508del mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene or who have one copy of the F508del mutation and one mutation in another CFTR gene. Health Canada’s approval of Symdeko was based on data from the Phase 3 EVOLVE and EXPAND trials, which enrolled 744 individuals over 12 years old with cystic fibrosis and with two copies of the F508del mutation or one F508del mutation and another mutation assumed to be responsive to tezacaftor/ivacaftor.

  • How Is VRTX Positioned Leading Up to Its Q2 2018 Earnings?
    Market Realist10 days ago

    How Is VRTX Positioned Leading Up to Its Q2 2018 Earnings?

    Vertex Pharmaceuticals (VRTX) generated net revenue of $638 million from the sales of cystic fibrosis products in the first quarter, reflecting ~33% YoY (year-over-year) growth.

  • Analysts Are Mostly Feeling Good about Vertex Pharmaceuticals
    Market Realist11 days ago

    Analysts Are Mostly Feeling Good about Vertex Pharmaceuticals

    In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.

  • Company News For Jul 2, 2018
    Zacks14 days ago

    Company News For Jul 2, 2018

    Companies in the news are: STZ,KBH,VRTX,FCAU

  • Vertex's Shares Rally as a Rival's CF Candidate Disappoints
    Zacks14 days ago

    Vertex's Shares Rally as a Rival's CF Candidate Disappoints

    Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

  • ACCESSWIRE14 days ago

    Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Acceleron Pharma and Vertex Pharmaceuticals both saw big gains on Friday on separate positive catalysts last week. Acceleron and Celgene reported strong results ...

  • Why Vertex Pharmaceuticals Rose over 15%
    Market Realist14 days ago

    Why Vertex Pharmaceuticals Rose over 15%

    Vertex Pharmaceuticals (VRTX) stock rose on June 29 after peer Galapagos (GLPG) announced mediocre mid-stage study data for its cystic fibrosis drug. Galapagos also announced that its potential development collaboration with AbbVie (ABBV) for a different triple combination therapy for cystic fibrosis is most likely being dropped, as AbbVie pulled out of the talks.

  • Barrons.com16 days ago

    After the Bell: For the Dow, a Good Quarter, but a Bad Year

    Stocks added to Thursday's gains to end the quarter on a high note, with the Dow Jones Industrial Average up 0.2%. The Dow Jones Industrial Average rose  55.36 points, or 0.2%, to 24.271.41. The Nasdaq Composite, which escaped some of the trade war turmoil, takes the cake however: It 0.1% to 7510.30 today, but it's up 6.3% this quarter and has jumped 8.8% since the start of 2018.  Global stocks had their worst start to the year since 2010, but the fact that all three major indexes managed to notch gains for the second quarter seems like a feat, given the near-constant worry about tariffs that repeatedly torpedoed the market of late.

  • Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out
    Investor's Business Daily16 days ago

    Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out

    Vertex Pharmaceuticals shares rocketed to a three-month high Friday after rival Galapagos released disappointing for a cystic fibrosis treatment.

  • TheStreet.com16 days ago

    Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

    released mediocre mid-stage test results for its new cystic fibrosis drug Friday. Shares for the Boston-based Vertex rose $20.78 -- 14.1% -- to $168.49 on the news that Galapagos' FEV-1 improvements in its Phase II trial came in below Wall Street's expectations. Galapagos, meanwhile, fell $4.29 -- 4.48% -- $91.52 in mid-afternoon trading as the company also announced that its possible collaboration with AbbVie Inc.

  • Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today
    Motley Fool17 days ago

    Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today

    The biotech gets a big win thanks to a potential competitor's pipeline disappointment.

  • Bad News Delivers a Decisive Blow to Galapagos N.V.
    Motley Fool17 days ago

    Bad News Delivers a Decisive Blow to Galapagos N.V.

    Galapagos shares are tumbling following disappointing results from a cystic fibrosis trial.

  • Stocks Jump As Nike, Wells Fargo, Vertex Lead Early Rally
    Investor's Business Daily17 days ago

    Stocks Jump As Nike, Wells Fargo, Vertex Lead Early Rally

    A positive reading on May consumer spending data, bank stress tests and Nike earnings results put a positive spin on the start of final session of June, and of the second quarter.

  • Benzinga17 days ago

    Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...

  • Premarket: Futures Rise As Banks Rally On Stress Test; Nike Spikes
    Investor's Business Daily17 days ago

    Premarket: Futures Rise As Banks Rally On Stress Test; Nike Spikes

    Stock futures gained premarket strength Friday, as banks rallied and Nike and KB Home posted strong gains, but investors were eyeing China's markets and personal spending data due early Friday.

  • Business Wire18 days ago

    Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that Health Canada approved PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or who have one copy of the F508del mutation and one of the following mutations in the CFTR gene: P67L, D110H, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. “This approval is an important milestone in our journey to enhance and expand treatment options for people living with CF,” said Reshma Kewalramani, M.D., Executive Vice President and Chief Medical Officer at Vertex.

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $1.59 billion.

  • The 10 Fastest-Growing Stocks to Invest In Right Now
    InvestorPlace20 days ago

    The 10 Fastest-Growing Stocks to Invest In Right Now

    The company is the name behind a large collection of 3D modeling and computer-aided drafting platforms — most of which are sold on a subscription basis. Who know cloud-based drafting software could help create one of the market’s top fast-growing stocks?

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • Drug pricing debate could heat up in July
    CNBC Videos10 days ago

    Drug pricing debate could heat up in July

    CNBC's Meg Tirrell reports on drug prices and hikes that have already occurred this month. With Michael Yee, Jefferies.